Literature DB >> 25432859

Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.

Ankita Thakur1, Harpreet Kaur, Sukhbir Kaur.   

Abstract

Visceral leishmaniasis (VL) caused by Leishmania donovani is a life-threatening disease involving uncontrolled parasitization of vital organs. Drugs to treat leishmaniasis have one or more limitations or insufficiencies in the long run. A safe and efficacious vaccine to control this disease is needed. Killed antigens that could be safer as vaccines have shown limited efficacy in clinical trials. Immunogenic enhancement with appropriate adjuvants may thus be required to elicit protective immunity based on antibodies and effector T-cell functions. Therefore, it is essential to search for adjuvant to enhance the immunogenicity of killed vaccines and to induce protection against leishmaniasis. So, the aim of the present study was to compare the effectiveness of four adjuvants, i.e. alum, saponin, monophosphoryl lipid A, cationic liposome in combination with Killed Leishmania donovani (KLD) antigen against murine VL. Animals were immunized subcutaneously thrice at an interval of 2 weeks with a final volume of 100 μl per dose. Challenge infection was given 2 weeks after last booster. Mice were sacrificed 15 days after last immunization and on 30, 60 and 90 post-infection/challenge days. The protective efficacy of vaccines was revealed by significant reduction in parasite burden and enhanced DTH responses in comparison with the infected controls. Immunized animals also generated significant levels of Th1 cytokines and increased production of IgG2a, thus indicating the generation of a protective Th1 response. All the adjuvants imparted significant protection, but liposomal formulation was most effective followed by KLD + MPL-A, KLD + saponin, KLD + alum and KLD antigen.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25432859     DOI: 10.1007/s00430-014-0367-9

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  63 in total

Review 1.  Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs.

Authors:  Diana Felnerova; Jean-François Viret; Reinhard Glück; Christian Moser
Journal:  Curr Opin Biotechnol       Date:  2004-12       Impact factor: 9.740

2.  Safety and skin delayed-type hypersensitivity response in vervet monkeys immunized with Leishmania donovani sonicate antigen delivered with adjuvants.

Authors:  Joshua M Mutiso; John C Macharia; Evans Taracha; Kellern Wafula; Hitler Rikoi; Michael M Gicheru
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2012 Jan-Feb       Impact factor: 1.846

3.  IL-12 is required to maintain a Th1 response during Leishmania major infection.

Authors:  A Y Park; B D Hondowicz; P Scott
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

4.  Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.

Authors:  F Afrin; N Ali
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae.

Authors:  M Nateghi Rostami; H Keshavarz; A Khamesipour
Journal:  Trop Biomed       Date:  2010-04       Impact factor: 0.623

6.  Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.

Authors:  M Tafaghodi; M Eskandari; M Kharazizadeh; A Khamesipour; M R Jaafari
Journal:  Trop Biomed       Date:  2010-12       Impact factor: 0.623

7.  Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response.

Authors:  K E Squires; R D Schreiber; M J McElrath; B Y Rubin; S L Anderson; H W Murray
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

8.  Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.

Authors:  Tejinder Kaur; Ankita Thakur; Sukhbir Kaur
Journal:  J Parasit Dis       Date:  2012-09-06

9.  Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice.

Authors:  D J Bradley; J Kirkley
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

10.  Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.

Authors:  Rajatava Basu; Suniti Bhaumik; Arun Kumar Haldar; Kshudiram Naskar; Tripti De; Syamal Kumar Dana; Peter Walden; Syamal Roy
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

View more
  1 in total

1.  Attenuation of the Diffuse Noxious Inhibitory Controls in Chronic Joint Inflammatory Pain Is Accompanied by Anxiodepressive-Like Behaviors and Impairment of the Descending Noradrenergic Modulation.

Authors:  Raquel Pereira-Silva; José Tiago Costa-Pereira; Raquel Alonso; Paula Serrão; Isabel Martins; Fani L Neto
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.